DP
VTGN icon

Diadema Partners’s VistaGen Therapeutics VTGN Stock Holding History

Diadema Partners’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Buy
+57,700
New +$34.8K ﹤0.01% 143
2026
Q1 		– Sell
-106,500
Closed -$70.5K – 210
2025
Q4 		$70.5K Buy
106,500
+6,300
+6% +$22.8K 0.01% 139
2025
Q3 		$356K Buy
100,200
+100,000
+50,000% +$299K 0.09% 104
2025
Q2 		$400 Hold
200
– – ﹤0.01% 95
2025
Q1 		$500 Hold
200
– – ﹤0.01% 102
2024
Q4 		$590 Buy
+200
New +$563 ﹤0.01% 107

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Diadema Partners's VTGN Position: Q2 2026 in Review

Diadema Partners sold out of VistaGen Therapeutics (VTGN) in Q2 2026, closing a stake of 105,428 shares — an estimated $63.6K sold.

Diadema Partners first reported a position in VTGN in Q4 2024 and held it in 6 quarters. The position peaked at $1.41M in Q1 2025. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Diadema Partners reported no remaining VistaGen Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Diadema Partners sold 105,428 VistaGen Therapeutics shares in Q2 2026, an estimated $63.6K.
  • Diadema Partners first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 6 quarters.
  • Diadema Partners's VistaGen Therapeutics position peaked at $1.41M in Q1 2025.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.